

Yves-Marie Pers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/443813/publications.pdf>

Version: 2024-02-01

38
papers

1,539
citations

567144

15
h-index

377752

34
g-index

40
all docs

40
docs citations

40
times ranked

3182
citing authors

#	ARTICLE	IF	CITATIONS
1	Adipose Mesenchymal Stromal Cell-Based Therapy for Severe Osteoarthritis of the Knee: A Phase I Dose-Escalation Trial. <i>Stem Cells Translational Medicine</i> , 2016, 5, 847-856.	1.6	389
2	Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. <i>Drug Safety</i> , 2018, 41, 919-931.	1.4	301
3	Non- TNF -Targeted Biologic vs a Second Anti- TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti- TNF Drug. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1172.	3.8	160
4	Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. <i>Rheumatology</i> , 2014, 53, 76-84.	0.9	89
5	Circulating miRNA-125b Is a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-9.	1.4	83
6	X-Linked miRNAs Associated with Gender Differences in Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1852.	1.8	55
7	Efficacy and safety of tocilizumab in elderly patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2015, 82, 25-30.	0.8	54
8	Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 349-355.	0.5	52
9	Implication of IL-17 in Bone Loss and Structural Damage in Inflammatory Rheumatic Diseases. <i>Mediators of Inflammation</i> , 2019, 2019, 1-9.	1.4	37
10	Handgrip strength measured by a dynamometer connected to a smartphone: a new applied health technology solution for the self-assessment of rheumatoid arthritis disease activity. <i>Rheumatology</i> , 2016, 55, 897-901.	0.9	32
11	A randomized prospective open-label controlled trial comparing the performance of a connected monitoring interface versus physical routine monitoring in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 1659-1668.	0.9	27
12	Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2016, 8, 107-118.	1.2	21
13	Development and Validation of a Self-Administered Multidimensional Prognostic Index to Predict Negative Health Outcomes in Community-Dwelling Persons. <i>Rejuvenation Research</i> , 2019, 22, 299-305.	0.9	20
14	A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 368-374.	0.9	18
15	Characteristics of the musculoskeletal symptoms observed among survivors of Ebola virus disease in the Postebogui cohort in Guinea. <i>Rheumatology</i> , 2017, 56, 2068-2072.	0.9	17
16	Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1247.	1.8	16
17	The Challenges of Telemedicine in Rheumatology. <i>Frontiers in Medicine</i> , 2021, 8, 746219.	1.2	16
18	Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e56-e56.	0.5	15

#	ARTICLE	IF	CITATIONS
19	Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial Autologous AD-SVF versus placebo in systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 1936-1947.	0.9	15
20	Efficacy of Tocilizumab in the treatment of Eosinophilic fasciitis: Report of one case. <i>Joint Bone Spine</i> , 2015, 82, 460-461.	0.8	14
21	Evaluation Design of EFFICHRONIC: The Chronic Disease Self-Management Programme (CDSMP) Intervention for Citizens with a Low Socioeconomic Position. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1883.	1.2	14
22	Heart Involvement in a Woman Treated with Hydroxychloroquine for Systemic Lupus Erythematosus Revealing Fabry Disease. <i>Journal of Rheumatology</i> , 2016, 43, 997-998.	1.0	13
23	Association of TRAF1-C5 with risk of uveitis in juvenile idiopathic arthritis. <i>Joint Bone Spine</i> , 2017, 84, 305-308.	0.8	13
24	Revisiting the cardiovascular risk of hydroxychloroquine in RA. <i>Nature Reviews Rheumatology</i> , 2020, 16, 671-672.	3.5	12
25	Understanding Long-term Evolution and Predictors of Sequelae of Ebola Virus Disease Survivors in Guinea: A 48-Month Prospective, Longitudinal Cohort Study (PostEboGui). <i>Clinical Infectious Diseases</i> , 2021, 73, 2166-2174.	2.9	12
26	TMEM187-IRAK1 Polymorphisms Associated with Rheumatoid Arthritis Susceptibility in Tunisian and French Female Populations: Influence of Geographic Origin. <i>Journal of Immunology Research</i> , 2017, 2017, 1-12.	0.9	9
27	Management of patients with rheumatoid arthritis by telemedicine: connected monitoring. A randomized controlled trial. <i>Joint Bone Spine</i> , 2022, 89, 105368.	0.8	8
28	TNFR2 polymorphism is associated with response to TNF blockers in rheumatoid arthritis patients seronegative for ACPA. <i>Joint Bone Spine</i> , 2014, 81, 370-372.	0.8	7
29	Immunomodulation with IL-17 and TNF- α in spondyloarthritis: focus on the eye and the central nervous system. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110258.	1.2	5
30	Impact of the chronic disease self-management program (CDSMP) on self-perceived frailty condition: the EU-EFFICHRONIC project. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110567.	1.1	5
31	Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study. <i>BMC Rheumatology</i> , 2020, 4, 5.	0.6	4
32	Mesenchymal Stromal Cells: Updates and Therapeutic Outlook in Rheumatic Diseases. <i>Journal of Clinical Medicine</i> , 2013, 2, 201-213.	1.0	3
33	EFFICHRONIC study protocol: a non-controlled, multicentre European prospective study to measure the efficiency of a chronic disease self-management programme in socioeconomically vulnerable populations. <i>BMJ Open</i> , 2019, 9, e032073.	0.8	2
34	Le polymorphisme du TNFR2 est associ�� la r��ponse aux anti-TNF- α dans la polyarthrite rhumato��de chez les patients sans anticorps anti-CCP. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014, 81, 349-351.	0.0	0
35	An atypical sciatica revealing a rhabdomyolysis. <i>Joint Bone Spine</i> , 2014, 81, 452.	0.8	0
36	Le d��clin r��g��n��ratif de la gonarthrose: mythe ou r��alit��? <i>Revue Du Rhumatisme Monographies</i> , 2016, 83, 162-165.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Cholangiocarcinoma occurring in a patient with type 1 Gaucher disease treated with velaglucerase alfa enzyme replacement therapy: First case report. Blood Cells, Molecules, and Diseases, 2018, 68, 112-114.	0.6	0
38	Que nous apporte lâ€™IRM dans lâ€™arthrose (diagnostic, pronostic, traitement)Â? Focus sur le genou arthrosique. Revue Du Rhumatisme Monographies, 2021, 88, 123-128.	0.0	0